A chimeric antigen receptor (CAR) T cell targeting CD19 that integrates PD-1 and TIGIT has shown effective anti-tumor activity in relapsed or refractory large B-cell lymphoma, and significantly enhanced CAR-T persistence cells in vivo (57). Here, PDCD1 is linked to neoplasm.